RS Oncology LLC
🇺🇸United States
Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma
Phase 1
Recruiting
- Conditions
- Mesotheliomas PleuralMesothelioma; LungMalignant Pleural EffusionMalignant Pleural MesotheliomaPleural Effusion, MalignantMesothelioma
- Interventions
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- RS Oncology LLC
- Target Recruit Count
- 186
- Registration Number
- NCT05278975
- Locations
- 🇬🇧
The Royal Marsden, London, United Kingdom
🇬🇧Guys and St Thomas NHS Foundation Trust, London, United Kingdom
🇬🇧The Christie NHS, Manchester, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath